Technical Analysis for IONS - Ionis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 79.52 1.25% 0.98
IONS closed up 1.25 percent on Monday, March 18, 2019, on 1.36 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical IONS trend table...

Date Alert Name Type % Chg
Mar 18 New 52 Week Closing High Bullish 0.00%
Mar 18 Pocket Pivot Bullish Swing Setup 0.00%
Mar 18 New 52 Week High Strength 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Overbought Stochastic Strength 0.00%
Mar 18 Up 3 Days in a Row Strength 0.00%
Mar 18 Up 4 Days in a Row Strength 0.00%
Mar 18 Up 5 Days in a Row Strength 0.00%
Mar 15 New 52 Week Closing High Bullish 1.25%
Mar 15 New 52 Week High Strength 1.25%

Older signals for IONS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company's drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington's disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing's syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Cancer Organ Systems Diabetes Cancers Drug Discovery Disorders Prostate Cancer Genetics Obesity Multiple Sclerosis Neurological Disorders Isis Huntington's Disease Spinal Muscular Atrophy Treatment Of Diabetes Hereditary Angioedema Orphan Drugs Acromegaly Cushing's Syndrome Hepatitis C Virus Infection Therapeutic Gene Modulation Antisense RNA Severe And Rare Diseases Familial Amyloid Polyneuropathy Familial Chylomicronemia Syndrome Familial Partial Lipodystrophy Homozygous Familial Hypercholesterolemia
Is IONS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 79.72
52 Week Low 39.07
Average Volume 1,006,587
200-Day Moving Average 51.8813
50-Day Moving Average 62.2364
20-Day Moving Average 69.003
10-Day Moving Average 74.158
Average True Range 2.2434
ADX 50.99
+DI 46.77
-DI 8.5797
Chandelier Exit (Long, 3 ATRs ) 72.9898
Chandelier Exit (Short, 3 ATRs ) 63.7102
Upper Bollinger Band 82.9856
Lower Bollinger Band 55.0204
Percent B (%b) 0.88
BandWidth 40.527513
MACD Line 4.9493
MACD Signal Line 4.0991
MACD Histogram 0.8503
Fundamentals Value
Market Cap 9.88 Billion
Num Shares 124 Million
EPS 0.21
Price-to-Earnings (P/E) Ratio 378.67
Price-to-Sales 13.91
Price-to-Book 31.29
PEG Ratio -7.79
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 82.09
Resistance 3 (R3) 81.87 80.79 81.66
Resistance 2 (R2) 80.79 80.14 80.90 81.51
Resistance 1 (R1) 80.16 79.74 80.48 80.38 81.37
Pivot Point 79.08 79.08 79.24 79.19 79.08
Support 1 (S1) 78.45 78.43 78.77 78.67 77.67
Support 2 (S2) 77.37 78.03 77.48 77.53
Support 3 (S3) 76.74 77.37 77.38
Support 4 (S4) 76.96